Founded in 2018, Broadwood Capital operates as an alternative lender headquartered in London, United Kingdom. Specializing in real estate investment, development, and construction, the firm focuses its expertise on various sectors within the United Kingdom.
Neal Clifton Bradsher, the founder of Broadwood Capital, Inc., established the firm in 2002. Presently, he serves as an Independent Director at Lineage Cell Therapeutics, Inc., a position he has held since 2009. Bradsher's previous roles include Managing Director at Whitehall Asset Management, Inc. from 1999 to 2002, Chief Operating Officer at Campbell Advisors, Inc. from 1995 to 1999, Analyst at Alex. Brown & Sons, Inc., and Senior Equity Analyst at Hambrecht & Quist Philippines, Inc. He earned his undergraduate degree from Yale College.
Broadwood Capital, operating as a hedge fund, serves two clients and manages discretionary assets totaling $1,301,065,766, as reported in their Form ADV filed on March 31, 2023. Their most recent 13F filing for the fourth quarter of 2023 indicates holdings of $1,173,335,414 in managed 13F securities, with a top 10 holdings concentration of 100%. Of particular note, Broadwood Capital's largest holding comprises 8,488,017 shares of Monster Beverage Corp.
| Fund Name: | Broadwood Capital |
| Manager | Neal Clifton Bradsher |
| Portfolio Value | $1,330,986,671 |
| Change This QTR | +1.13% |
| No. | Security | Ticker | Shares | Value | Activity | % Port | History |
|---|---|---|---|---|---|---|---|
| 1. | MNST | 8,295,690 | $491,768,503 | -3% | 36.94% | ||
| 2. | STAA | 10,768,430 | $412,215,500 | +3% | 30.97% | ||
| 3. | AXON | 760,062 | $237,808,199 | 17.86% | |||
| 4. | IEF | 566,000 | $119,029,800 | 8.94% | |||
| 5. | LCTX | 41,666,255 | $61,666,057 | +20% | 4.63% |
